Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A, Whitfield D, Siegel E, Barlogie B, Fink L, Tricot G. Zangari M, et al. Among authors: badros a. Blood Coagul Fibrinolysis. 2002 Apr;13(3):187-92. doi: 10.1097/00001721-200204000-00003. Blood Coagul Fibrinolysis. 2002. PMID: 11943931 Clinical Trial.
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, Van Rhee F, Cottler-Fox M, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G. Lee CK, et al. Among authors: badros a. Bone Marrow Transplant. 2002 Dec;30(12):873-8. doi: 10.1038/sj.bmt.1703715. Bone Marrow Transplant. 2002. PMID: 12476279
Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone.
Desikan KR, Tricot G, Munshi NC, Anaissie E, Spoon D, Fassas A, Toor A, Zangari M, Badros A, Morris C, Vesole DH, Siegel D, Jagannath S, Barlogie B. Desikan KR, et al. Among authors: badros a. Br J Haematol. 2001 Jan;112(1):242-7. doi: 10.1046/j.1365-2141.2001.02498.x. Br J Haematol. 2001. PMID: 11167811 Free article.
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions.
Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N, Zangari M, Mehta J, Toor A, Cottler-Fox M, Fassas A, Anaissie E, Schichman S, Tricot G. Badros A, et al. Blood. 2001 May 1;97(9):2574-9. doi: 10.1182/blood.v97.9.2574. Blood. 2001. PMID: 11313244 Free article. Clinical Trial.
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.
Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G. Barlogie B, et al. Among authors: badros a. Blood. 2001 Jul 15;98(2):492-4. doi: 10.1182/blood.v98.2.492. Blood. 2001. PMID: 11435324 Free article. Clinical Trial.
Thalidomide in the management of multiple myeloma.
Barlogie B, Zangari M, Spencer T, Fassas A, Anaissie E, Badros A, Cromer J, Tricot G. Barlogie B, et al. Among authors: badros a. Semin Hematol. 2001 Jul;38(3):250-9. doi: 10.1016/s0037-1963(01)90017-4. Semin Hematol. 2001. PMID: 11486313 Review.
155 results